REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
01/09/2025
Voltar para busca
Dado oficial do USPTO
ROVIPIA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
02/09/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 44
Data de depósito
02/12/2019
Data de registro
01/09/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/09/2020
Última transação
02/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
CH
Examinador
CORNWELL, ANDREA
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; biological preparations for the treatment of bacterial infectionsviral infectionsinflammatory disordersfungal infectionscardiovascular diseases and disordersdermatological conditionsrespiratory diseases and disorderscentral nervous system diseases and disordersgastrointestinal diseases and disorderskidney diseasesdiabeteshypertensionskin disorderscancer and tumorsallergiesbone diseasesdiseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe Musculo-skeletal system and the genitourinary system; biological preparations for use in hematology and in tissue and organ transplantation; biological preparations for prevention and treatment of eye diseases and conditions; biological preparations for the prevention and treatment of heart rhythm disorders; biological preparations for the prevention and treatment of immune system related diseases and disorders and stem cells for pharmaceutical and medical use
Classe 44
Collection and preservation of blood; collection and preservation services for tissue and cellscollection and banking of umbilical cord tissue perivascular stem cells; medical diagnostic services; medical treatment services; provision of medical information and data for diagnosis and medical treatment
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/01/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
31/12/2020
FIMP
FINAL DISPOSITION PROCESSED
31/12/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/12/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
01/09/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/06/2020
PUBO
PUBLISHED FOR OPPOSITION
16/06/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/05/2020
ALIE
ASSIGNED TO LIE
07/05/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/04/2020
RFNT
REFUSAL PROCESSED BY IB
10/04/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/03/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
18/03/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/03/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
18/03/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/03/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/03/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
18/03/2020
RFRR
REFUSAL PROCESSED BY MPU
18/03/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/02/2020
CNRT
NON-FINAL ACTION WRITTEN
27/02/2020
DOCK
ASSIGNED TO EXAMINER
27/02/2020
MAFR
APPLICATION FILING RECEIPT MAILED
18/02/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/02/2020
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
11/02/2020
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
06/02/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ROVIPIA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.